FBR & Co restated their outperform rating on shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) in a research note issued to investors on Wednesday. The brokerage currently has a $16.00 target price on the biotechnology company’s stock.
Other equities analysts have also recently issued reports about the company. Zacks Investment Research raised Conatus Pharmaceuticals from a hold rating to a buy rating and set a $2.00 price target for the company in a report on Friday, November 25th. SunTrust Banks, Inc. reissued a buy rating and issued a $26.00 price target (up from $17.00) on shares of Conatus Pharmaceuticals in a report on Friday, December 23rd. HC Wainwright boosted their price target on Conatus Pharmaceuticals from $9.00 to $18.00 and gave the stock a buy rating in a report on Tuesday, December 20th. Finally, Stifel Nicolaus boosted their price target on Conatus Pharmaceuticals from $5.00 to $7.00 and gave the stock a buy rating in a report on Tuesday, December 20th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $13.25.
Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 4.69 on Wednesday. Conatus Pharmaceuticals has a 1-year low of $1.45 and a 1-year high of $6.30. The firm’s market cap is $118.06 million. The company’s 50-day moving average price is $4.77 and its 200 day moving average price is $3.16.
Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Wednesday, March 15th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.09. During the same period in the prior year, the business earned ($0.30) earnings per share. On average, equities analysts expect that Conatus Pharmaceuticals will post ($0.91) earnings per share for the current fiscal year.
Your IP Address:
Institutional investors have recently added to or reduced their stakes in the company. ING Groep NV bought a new position in Conatus Pharmaceuticals during the fourth quarter worth $110,000. Ellington Management Group LLC bought a new position in Conatus Pharmaceuticals during the fourth quarter worth $154,000. Courage Capital Management LLC bought a new position in Conatus Pharmaceuticals during the third quarter worth $200,000. United Capital Financial Advisers LLC boosted its position in Conatus Pharmaceuticals by 5.7% in the fourth quarter. United Capital Financial Advisers LLC now owns 154,578 shares of the biotechnology company’s stock worth $815,000 after buying an additional 8,369 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Conatus Pharmaceuticals by 193.5% in the fourth quarter. Renaissance Technologies LLC now owns 183,700 shares of the biotechnology company’s stock worth $968,000 after buying an additional 121,100 shares during the period. 15.90% of the stock is owned by institutional investors.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/conatus-pharmaceuticals-inc-cnat-earns-outperform-rating-from-fbr-co/1708625.html
Receive News & Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.